Circassia Pharmaceuticals Share Price (CIR)

60.30 -0.70 (-1.15%) delayed: 11:03AM GMT
Bid price 60.00 Open price 58.00
Ask price 60.60 Prev close 61.00
High price 60.90 Spread 0.99%
Low price 57.70 Volume 55,823

Register now for FREE live Circassia Pharmaceuticals share prices, Circassia Pharmaceuticals stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Circassia Pharmaceuticals Level 2 Data, indepth research tools and investor commentary for Circassia Pharmaceuticals (CIR) and other London Stock Exchange equities.

Circassia Pharmaceuticals Share Price Chart

Advanced Charts >>

Register now for FREE Circassia Pharmaceuticals share price charts

Circassia Pharmaceuticals Share Price Information

Name Circassia Pharmaceuticals Epic CIR
Sector Pharmaceuticals & Biotechnology ISIN GB00BJVD3B28
Activites Circassia Pharmaceuticals plc is a world-class specialty pharmaceutical business focused on respiratory disease. In addition to its market-leading NIOX products, the Company recently established a collaboration with AstraZeneca in the US in which it promotes the chronic obstructive pulmonary disease (COPD) treatment Tudorza, and has the US commercial rights to late-stage COPD product Duaklir. Circassia's development pipeline includes a range of respiratory medicines. The Company's lead asthma treatment targets substitution of GSK's Flixotide pMDI and was approved in the UK. Circassia is also developing a direct substitute for Seretide pMDI, and its pipeline includes a number of inhaled medicines for COPD, including single and combination dose products. Index n/a

Circassia Pharmaceuticals Key Numbers

Latest Share Price (p) 60.30 Net Gearing (%) 33.08
Market Capitalisation (£m) 217.96 Gross Gearing (%) 44.14
Shares in issue (m) 357.30 Debt Ratio 39.51
P/E Ratio -1.97 Debt-to-Equity Ratio 0.83
Total dividends per share (p) 0.00 Assets / Equity Ratio 1.79
Dividend Yield (%) 0.00 Price to book value 0.97
Dividend cover (x) 0.00 ROCE (%) -30.57
Earning per share (p) -31.00 EPS Growth (%) 35.42
52 week high / low 104.60 / 48.00 DPS Growth (%) n/a

Circassia Pharmaceuticals Director Deals

Dec.Date Type Director Pos No. of Shares
17/07/2017 EXR Steven Harris CEO 535,375
18/09/2015 SELL Charles Swingland RES 1,230,000
18/09/2015 SELL Charles Swingland RES 9,000
18/09/2015 SELL Charles Swingland RES 754,548
27/03/2014 EXR Dr Rod Hafner ED 212,375

More Circassia Pharmaceuticals Director Deals >>

Circassia Pharmaceuticals Company News

12:10 11/12/2018

Option exercised for Tudorza from AstraZeneca

RNS Number : 0980K Circassia Pharmaceuticals Plc 11 December 2018   Circassia to Exercise Option for Full US Commercial Rights to COPD Treatment Tudorza® from AstraZeneca   Oxford, UK - 11 December 2018: Circassia Pharmaceuticals plc ("Circassia" or "the Company";...

17:59 10/12/2018

Posting of Shareholder Circular

RNS Number : 0341K Circassia Pharmaceuticals Plc 10 December 2018   CIRCASSIA PHARMACEUTICALS PLC POSTING OF SHAREHOLDER CIRCULAR Oxford, UK - 10 December 2018: Circassia Pharmaceuticals plc ("Circassia" or "the Company") (LSE: CIR), a specialty pharmaceutical company...

12:59 10/12/2018

Proposed admission to trading on AIM

RNS Number : 9947J Circassia Pharmaceuticals Plc 10 December 2018   NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   CIRCASSIA...

More Circassia Pharmaceuticals Company News >>

Register now for FREE Circassia Pharmaceuticals company news

Circassia Pharmaceuticals Share Price Discussions

No Circassia Pharmaceuticals Share Price Discussions

Register now for FREE Circassia Pharmaceuticals share price discussions